DENGUE VACCINE DEVELOPMENT

Award Information
Agency: Department of Defense
Branch: Army
Contract: N/A
Agency Tracking Number: 3977
Amount: $553,000.00
Phase: Phase II
Program: SBIR
Awards Year: 1988
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Hawaii Biotechnology Group Inc
99-193 Aiea Heights Dr, Aiea, HI, 96701
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Morton Mandel
 (808) 487-5565
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE ULTIMATE OBJECTIVE OF THIS PROJECT IS THE PRODUCTION OF A DENGUE VACCINE. THE FOUR DENGUE VIRUSES (SEROTYPES) AS A GROUP ARE BY FAR THE MOST IMPORTANT VIRUSES TRANSMITTED TO MAN BY ARTHROPODS AND IN TERMS OF GLOBAL MORBIDITY ARE RESPONSIBLE FOR SEVERAL HUNDRED THOUSAND TO SEVERAL MILLION CASES ANNUALLY. IN PHASE I RANDOM FRAGMENTS OF THE DENGUE VIRUS 2 (RNA) GENOME WILL BE CLONED INTO A BACTERIAL EXPRESSION VECTOR. THESE RANDOMLY GENERATED FRAGMENTS WILL BE PRODUCED IN TWO WAYS TO ENSURE COMPLETE COVERAGE OF THE RNA GENOME.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government